Multidrug Resistance Protein

Multidrug Resistance Protein (P-Glycoprotein; MDR1)

Multidrug resistance protein in recurrent breast cancer.

1885 remained otherwise well until January, 1996, when he developed recurrent biliary stricturing with jaundice and worsening diarrhoea. Trough cyclosporin concentrations were considered sub-therapeutic at 60 ng/mL and so he was converted to Neoral therapy at the same dose. Several 12-h trough whole blood cyclosporin levels were taken over the following 2 months, and did not exceed 125 ng/mL. I...

Lung resistance-related protein: determining its role in multidrug resistance.

Resistance to cytotoxic drugs remains a major obstacle for the successful treatment of cancer (1). Over the past two decades, a great deal of information has emerged that elucidates how cancer cells become drug resistant. At least one prominent drugresistance mechanism in cancer cells is the reduction of intracellular drug concentration at the putative drug target. There are at least two mechan...

Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.

Sorafenib and sunitinib is a small molecule inhibitor of certain receptor tyrosine kinases, and have improved outcomes for patients with advanced renal cell carcinoma. Inhibitory concentration of 50% cell growth of sorafenib significantly rose to 6.4-fold in a multidrug resistance protein 2 (MRP2) transfected cell line versus control cell line. The concentration of sorafenib was significantly d...

Multidrug resistance associated proteins in multidrug resistance

Multidrug resistance proteins (MRPs) are members of the C family of a group of proteins named ATP-binding cassette (ABC) transporters. These ABC transporters together form the largest branch of proteins within the human body. The MRP family comprises of 13 members, of which MRP1 to MRP9 are the major transporters indicated to cause multidrug resistance in tumor cells by extruding anticancer dru...